Cluster headache management and beyond

Paolo Martelletti

To cite this article: Paolo Martelletti (2015) Cluster headache management and beyond, Expert Opinion on Pharmacotherapy, 16:10, 1411-1415

To link to this article:  http://dx.doi.org/10.1517/14656566.2015.1052741

Published online: 01 Jun 2015.

Submit your article to this journal

Article views: 248

View related articles

View Crossmark data
Cluster headache (CH) is the most common of the trigeminal autonomic cephalalgias (TACs) [1]. CH is a strictly lateralized and devastating periorbital headache, characterized with a very severe, excruciating pain and the presence of ipsilateral cranial autonomic symptoms, such as conjunctival injection, lacrimation and rhinorrhea. Lifetime prevalence is 1/1000 and a progressive reduction of the male/female ratio over the past decades has been demonstrated and is now 2.1:1 [2]. The peculiar timing over the day (1 – 8 attacks), in the entire active cluster period lasting 60 – 90 days, and in the span of the year particularly with the seasonal changes, renders this headache unique, very easy to diagnose and differentiate from other TACs [1]. Nevertheless, only 1/3 of these patients received the diagnosis of CH, with a diagnostic delay of 5.3 years and more than 2/3 of them never received any treatment. The most frequent clinical errors behind this delay are trigeminal neuralgia, migraine without aura, headache attributed to idiopathic intracranial hypertension, tension-type headache, depression, dental and sinus pathologies [3]. The strict laterality of pain, even though considered a clinical marker, might shift sides in a minority of patients, either within the bouts of the same cluster period or between the bouts of different cluster periods [4].

The natural history of this illness, which generally begins between 20/30 years of age, shows seasonal cluster periods with an unpredictable variability of their circannual rhythms. This leads to overestimate the effect of the administered therapy showing often a spontaneous prolonged remission. Only 10% of patients with episodic cluster headache (ECH) develop a chronic form (CCH) (> 180 days/year) and even fewer develop refractory or medically resistant chronic cluster headache (rCCH) [5].
The strong evidence supporting the pathophysiology of CH revolves around the suggestion of a posterior hypothalamic dysfunction (anatomic, endocrine, genetic, neuro-immunological and functional imaging). Scientists are therefore oriented toward its involvement [6] even if this solid hypothesis has been recently re-interpreted as an epiphenomenon [7]. Rare cases of secondary cluster-like headaches are ascribable to pituitary tumors, fungal cysts or dissection of the internal carotid artery and are extremely challenging for the clinician, also the expert one [8].

2. Early therapeutic management needed, but delayed diagnosis frustrates it

CH therapeutic management varies according to the three forms previously cited (ECH, CCH, rCCH).

Acute, transitional and preventative treatments can be applied to both ECH and CCH. The gold standard for the acute treatment of CH is subcutaneous sumatriptan, able to dissolve the attack in a handful of minutes [9-11]. Patients with previous ischemic and cardio-cerebral pathologies must be excluded from such therapy. Other sumatriptan or zolmitriptan formulations do not show, from a clinical point of view, the needed rapidity and completeness of action despite reported scientific evidence [12-16]. Indomethacin may, in some cases, be a helpful alternative even if there is no clear-cut evidence of its efficacy for CH. This drug is generally not recommended by international guidelines, and should not be used in the presence of arterial hypertension or gastric bleeding [17].

Pure oxygen inhalation at a flow of 7 – 15 l/min, delivered by facemask, possibly with reservoir for no more than 20 min, is safer and, on its own, showed a very meaningful effect on CH attack. The main concern is that, in some patients, it may delay the attacks rather than abort them. Unfortunately, oxygen presents applicative limitations in terms of portability [18,19].

Hyperbaric oxygen has been reported as a rescue alternative in chronic CH where other options resulted inopportune, but its intrinsic limits sum up with the lack of accessibility [20].

Recently, vagal nerve stimulation (VNS) has been proposed for the treatment of the attack and for prophylaxis, both in episodic and chronic CH. The initial experience indicates that noninvasive vagus nerve stimulation may be practical and effective as an acute and preventative treatment in CCH. This Class IV evidence technique should be confirmed by randomized controlled trials (RCTs) [21].

3. Transitional therapy is necessary, but beware of the carry-over phenomenon

In clinical situations showing a cluster period lasting up to 4 – 5 months with a risk of chronicization, transitional block of the greater occipital nerve with long-acting corticosteroids can be considered. This option may lead to a clinical amelioration and should be repeated cyclically. The limitation of this approach resides in the nonfamiliarity or the reluctance of the headache expert toward this mini-invasive but very easy technique [22].

Cortisone per os (prednisone 1 mg/kg with a tapering regimen) is still widely used but inadvisable since it causes the carry-over phenomenon of the cluster or, even worse, a violent rebound.

4. Preventative treatment as a cornerstone

The gold standard of preventative treatment is still verapamil taken at medium-high doses (from 360 mg/day up to 960 mg). The starting dose is always 360 mg ex abturo for patients with a clear absence of bradycardia (< 50 bpm), hypotension (< 100/60 mmHg) or other cardiac arrhythmias (atrioventricular block). Uncomfortable adverse effects of ankle edema [23] are tolerated by patients considering verapamil’s fast action, less than 72 h to crush the bouts.

Lithium is less handy than verapamil. It needs a longer latency period (up to 10 – 15 days) because of the need for progressive titration up to 900 – 1200 mg/day and a burdensome bimonthly evaluation of lithium levels (0.8 – 1.2 µmol/l); referential parameter for an effective therapeutic action, with important inter-individual variations. Serious side effects are hypothyroidism, diabetes insipidus and mental confusion.

The use of topiramate at optimal dosage (within 100 and 200 mg/day) is strongly limited by its serious side effects (slow titration, serious cognitive impairment) and contraindications (glaucoma, kidney stones, severe temporary weight loss and irreversible drop of visual acuity).

Melatonin may be included as preventative treatment on the basis of a small pilot RCT that demonstrated its clinical relevance in CH [24].

Other supposed preventative therapies with gabapentin, baclofen, levetiracetam, pizotifen, sodium valproate, testosterone, misoprostol, cimamide, warfarin, candesartan, acetumpate or other drugs no longer available, like dihydroergotamine and methysergide, are not clinically relevant.

The mentioned preventative treatments must be started at the first sight of activation/re-activation of the cluster period and must be continued for a period equal to 1.5 of the historical length of the patient’s single cluster. Shorter treatments might produce a temporal shift of the active period, even if this re-firing has a lower intensity. Therefore, the most appropriate semantic definition of the preventative therapy should be “control/suppression therapy” of the cluster period.

5. Beyond the reliable pharmacological triad

A hypothetical tripod for the therapy of CH can be summarized in sumatriptan, verapamil and corticosteroids. New therapeutic opportunities are now enriching the literature on the subject of migraines. These new compounds, monoclonal
antibodies against calcitonin gene-related peptide, could soon be available as preventative treatment of migraine [25] and, hopefully, for CH as well.

Furthermore, another important topic to be considered is patients’ knowledge regarding possible triggers. Patients should be educated to avoid any substance that, in the active phase of CH, might work as a strong activator of the bouts, like alcohol, nitroderivative drugs used for the treatment of angina pectoris, and phosphodiesterase inhibitors used for erectile dysfunction.

Therefore, only with better education of physicians at the different care levels (general practitioners, neurologists) and of patients, an early diagnosis is possible, since an adequate treatment of CH cuts the risk of chronicization to a minimum. A practical concise scheme for the management of CH is summarized in Figure 1.

It goes without saying that the introduction of new, more manageable and efficacious preventative drugs might stop the therapeutic alarm that often hovers around this impressive and psychologically destabilizing painful pathology. These drugs may also reduce the chronicization rate often linked to an inefficacy ab initio of the therapeutic preventative opportunities now available.

Another point to be mentioned regards the new invasive and noninvasive neuromodulation approaches for CCH. Despite promising new data, the European Headache Federation recommends caution in using these techniques [26] because only few controlled studies have, as yet, been carried out. It is important to avoid the disillusion produced in CCH patients when, more than 10 years ago, the scientific community celebrated as decisive, an extremely invasive and harmful therapeutic proposal [27], now abandoned [26,28].

Lastly, going beyond the actual management of CH, VNS seems to be promising but is still classified at Class IV evidence [21], while sphenopalatine ganglion stimulation shows contrasting evidence [29,30] that needs to be confirmed and validated through RCTs.

On the other hand, new hopes rely on the future application of an RCT efficacy study of LY2951742 in episodic CH. This drug, if approved, could change the management of CH rendering it very easy to use through a subcutaneous administration every 30 days [31].

**Declaration of interest**

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Bibliography

Papers of special note have been highlighted as either of interest (●) or of considerable interest (★★) to readers.

8. Edvardsson B. Symptomatic cluster headache: a review of 63 cases. Springerplus 2014;3:64
26. **An extremely updated official statement summarizing the state of the art on neuromodulation of chronic headaches.**

Affiliation
Paolo Martelletti
Sapienza University, Department of Clinical and Molecular Medicine, Rome, Italy
Tel: +39 06 33 77 51 10;
Fax: +39 06 33 77 51 11;
E-mail: paolo.martelletti@uniroma1.it